Characterisation of circulating microRNA-21 levels in patients with hypertrophic cardiomyopathy
Open Access
- 19 April 2020
- journal article
- research article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (4) , 51-56
Abstract
Aim. To study the levels of circulating microRNA-21 in patients with hypertrophic cardiomyopathy (HCM) of different ages. Materials and methods. The study included 49 patients with HCM. The proportion of females was 55.1%, males 44.9%. The average age was 50 [32; 65] (from 19 to 86 years). The control group for microRNA-21 included 44 healthy individuals, respectively, matched by the age and sex with the studied patients. Patients was made in accordance with the recommendations of the European society of cardiology. Plasma microRNA expression was determined by PCR with reverse transcription and real-time detection of results. The relative level of gene expression was calculated in accordance with the standard procedure 2-Ct. Results. Septal wall thickness at end diastole has a significant negative correlation with age in patients with HCM (r=-0.56; р0.001). PWTd (posterior wall thickness at end diastole) has a significant positive correlation with age in patients with HCM (r=0.67, р0.001). The level of circulating microRNA-21 in plasma is higher in patients with HCM compared to healthy individuals (5.28 [2.64; 13.96] and 0.84 [0.55; 1.23], respectively; p0.001). Significantly higher levels of microRNA-21 were found in young patients aged from 19 to 45 years with the symptomatic course of HCM (36.76 [5.66; 42.22]) compared to patients with asymptomatic course 45 years of age (2.81 [1.45; 5.28]; p0.002) and symptomatic patients 45 years (3.88 [2.16; 8.63]; p0.002).) The calculated risk of SCD was significantly higher in young symptomatic patients with HCM (6.01 [3.64; 9.67]) compared to patients with asymptomatic course 45 years (2.41 [1.21; 3.89]; p0.001) and symptomatic patients 45 years (2.56 [1.67; 4.41]; p0.001). Conclusion. The level of circulating microRNA-21 is significantly in patients with HCM compared to control group. The maximum level of circulating microRNA-21 was detected in patients with symptomatic course of HCM at the age of 45 years.Keywords
This publication has 20 references indexed in Scilit:
- 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathyEuropean Heart Journal, 2014
- Regulation of microRNA biogenesisNature Reviews Molecular Cell Biology, 2014
- Cardiac fibroblast–derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophyJournal of Clinical Investigation, 2014
- Circulating miR-29a, Among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients With Hypertrophic CardiomyopathyJACC, 2014
- MicroRNA 21 Inhibits Left Ventricular Remodeling in the Early Phase of Rat Model with Ischemia-reperfusion Injury by Suppressing Cell ApoptosisInternational Journal of Medical Sciences, 2012
- The magic and mystery of miR-21Journal of Clinical Investigation, 2010
- MicroRNA-21 in Cardiovascular DiseaseJournal of Cardiovascular Translational Research, 2010
- MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblastsNature, 2008
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14Cell, 1993